Bayer (ETR:BAYN) price target raised to 81.00EUR, reported today by Baader Wertpapierhandelsbank
- Updated: September 15, 2016
Just yesterday Bayer (ETR:BAYN) traded 7.14% lower at 91.44EUR. The company’s 50-day moving average is 0.04EUR and its two hundred day average is 0.03EUR. With the last stock price up 1.82% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. 10,000 shares of BAYN traded, up from ann average trading volume of 211.
Baader Wertpapierhandelsbank upped the target stock price of Bayer (ETR:BAYN) to 81EUR, stating a possible downside of -0.11%,
Previously on Monday August 29 2016, Citigroup Corp. released a statement about Bayer(ETR:BAYN) bumped the target price from 0.00EUR to 120.00EUR. At the time, this suggested an upside of 0.24%.
Recent Performance Graphic:
Bayer has a 52 week low of 0.03EUR and a 52 week high of 0.04EUR . Bayer’s market cap is presently 0.0 EUR.
Brief Synopsis On Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.